Straits Times Index
3,296.09 -8.90 (-0.27%) Nikkei
38,782.08 -138.18 (-0.36%) Hang Seng
19,398.97 +22.44 (+0.12%) FTSE 100
8,438.65 -7.15 (-0.08%) Bitcoin USD
65,482.60 -548.73 (-0.83%) CMC Crypto 200
1,375.85 -18.19 (-1.30%)
SNY May 2024 50.000 put
- Zacks
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.
- Benzinga
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
On Sunday, Pfizer (NYSE: PFE) and AstraZeneca Plc (NASDAQ: AZN) were among the pharmaceutical companies who announced they will be investing a total of nearly $1 billion in their operations in France, just ahead of this year’s “Choose France” business summit. Together with the domestic Sanofi (NASDAQ: SNY), Pfizer, AstraZeneca will together invest €1.87 billion which is more than $2 billion to expand their operations in the country. AstraZeneca committed 365 million euros, which is about $394 mi
- FX Empire
Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
The past five days have been a rollercoaster for Novavax investors, as the share price of the company skyrocketed by over 200% following the announcement of a major deal with French pharmaceutical giant Sanofi.
